1. Home
  2. SNDX vs WOOF Comparison

SNDX vs WOOF Comparison

Compare SNDX & WOOF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SNDX
  • WOOF
  • Stock Information
  • Founded
  • SNDX 2005
  • WOOF 1965
  • Country
  • SNDX United States
  • WOOF United States
  • Employees
  • SNDX N/A
  • WOOF N/A
  • Industry
  • SNDX Biotechnology: Pharmaceutical Preparations
  • WOOF Other Specialty Stores
  • Sector
  • SNDX Health Care
  • WOOF Consumer Discretionary
  • Exchange
  • SNDX Nasdaq
  • WOOF Nasdaq
  • Market Cap
  • SNDX 1.1B
  • WOOF 937.4M
  • IPO Year
  • SNDX 2016
  • WOOF 2021
  • Fundamental
  • Price
  • SNDX $14.75
  • WOOF $3.47
  • Analyst Decision
  • SNDX Strong Buy
  • WOOF Hold
  • Analyst Count
  • SNDX 10
  • WOOF 11
  • Target Price
  • SNDX $38.40
  • WOOF $3.91
  • AVG Volume (30 Days)
  • SNDX 2.0M
  • WOOF 4.7M
  • Earning Date
  • SNDX 11-04-2025
  • WOOF 08-28-2025
  • Dividend Yield
  • SNDX N/A
  • WOOF N/A
  • EPS Growth
  • SNDX N/A
  • WOOF N/A
  • EPS
  • SNDX N/A
  • WOOF N/A
  • Revenue
  • SNDX $77,933,000.00
  • WOOF $6,045,495,000.00
  • Revenue This Year
  • SNDX $585.73
  • WOOF $0.03
  • Revenue Next Year
  • SNDX $94.17
  • WOOF $1.36
  • P/E Ratio
  • SNDX N/A
  • WOOF N/A
  • Revenue Growth
  • SNDX 2126.66
  • WOOF N/A
  • 52 Week Low
  • SNDX $8.58
  • WOOF $2.28
  • 52 Week High
  • SNDX $22.50
  • WOOF $6.29
  • Technical
  • Relative Strength Index (RSI)
  • SNDX 47.48
  • WOOF 50.43
  • Support Level
  • SNDX $15.71
  • WOOF $3.57
  • Resistance Level
  • SNDX $16.50
  • WOOF $3.70
  • Average True Range (ATR)
  • SNDX 0.81
  • WOOF 0.23
  • MACD
  • SNDX -0.36
  • WOOF -0.02
  • Stochastic Oscillator
  • SNDX 2.73
  • WOOF 33.33

About SNDX Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

About WOOF Petco Health and Wellness Company Inc.

Petco Health and Wellness Co Inc is a pet specialty retailer focused on improving the lives of pets, pet parents, and its own partners with pet care centers in approximately 50 states, the District of Columbia and Puerto Rico. The Company also offers an expanded range of consumables, supplies, and services through its website and mobile app.

Share on Social Networks: